ATS (ATS) Stifel 2024 Cross Sector Insight Conference summary

Strategic evolution and business positioning

• Revenue has grown from under $1B to over $3B in seven years, with life sciences now comprising about half of the business.

• Portfolio shifted toward regulated, high-value markets like radiopharmaceuticals, lab water, and lyophilization.

• Five-year CAGR is approximately 18%, with bottom-line growth exceeding 20%.

• M&A and organic strategies have expanded capabilities and market reach.

Innovation, R&D, and technology integration

• Proprietary technology and IP now make up a larger share of offerings, reducing reliance on third-party integration.

• Symphony platform enables nearly double output with half the footprint for automation lines.

• AI is embedded in vision systems for defect detection and process optimization, saving millions annually.

• Data analytics tools Illuminate (on-prem) and PA-FACTS (cloud) provide actionable insights for customers.

Services and customer impact

• Services revenue has grown from low/mid-teens to mid-twenties as a percentage of total revenue.

• COVID accelerated the shift to services as mission-critical, with remote support and on-demand training.

• North America Operating Center enables real-time machine monitoring and output-based service agreements.

• Acquisitions bring immediate supply chain and service network benefits.